Tirzepatide denied for missing prior authorization by Cigna?
If the original prescription wasn't run through prior auth, the path is to submit a PA now with a medical-necessity letter — many plans then back-date approval to the date of service.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Cigna typically requires
T2DM diagnosis required (CNF-749); HbA1c ≥6.5% consistent with ADA.
What works in the appeal
See structured rules. Use plan-medical-necessity override + named guideline citations + step-therapy contraindications where applicable.
The Cigna angle on Tirzepatide
## Cigna's Prior Authorization Wall for Tirzepatide — What the CNF-749 Denial Actually Means
A "prior authorization required" denial from Cigna on tirzepatide (Mounjaro/Zepbound) is not a substantive denial — it is a procedural gate under Cigna Coverage Policy CNF-749 (and the parallel weight-management policy for Zepbound). The pharmacy benefit is administered by Express Scripts/Evernorth Care Solutions (Cigna's PBM since the 2018 acquisition), and the PA must route through the Evernorth electronic PA portal (CoverMyMeds or SureScripts), not through the Cigna medical benefit. Submissions misrouted to the medical side under J3490 or J-code billing are routinely rejected as "benefit determination pending" — that is the most common cause of an otherwise approvable script bouncing back.
For the T2DM indication (Mounjaro), CNF-749 requires three documentary elements: (1) ICD-10 E11.x diagnosis on the chart note, (2) HbA1c ≥6.5% within the prior 90 days — tracking the ADA 2024 Standards of Care diagnostic threshold, and (3) evidence the patient is not concurrently receiving another GLP-1 RA (semaglutide, liraglutide, dulaglutide). Cigna will also look for metformin trial/contraindication documentation under its tiered step protocol, though this is not absolute — a contraindication note (eGFR <30, GI intolerance, lactic acidosis history) satisfies the requirement under the policy's escape clause.
If the denial letter cites only "PA required" with no clinical reasoning, that itself is an ERISA §503 / 29 CFR §2560.503-1(g) disclosure failure: the plan must give the specific reason and reference to the plan provision. Demand the full denial letter and the CNF-749 version that was applied — Cigna updates these quarterly and applying a superseded version is reviewable error.
The step-therapy override rights under 29 USC §1185d (added by the Consolidated Appropriations Act, 2021) apply to fully-insured commercial plans and most ERISA self-funded plans that have adopted the federal framework: if the patient has previously failed or is contraindicated to the preferred agent, Cigna must grant an exception within 72 hours (standard) or 24 hours (urgent). Cite this statute by number in the appeal letter — boilerplate appeals get boilerplate denials.
For Medicare Advantage members on a Cigna MA plan, the Part D PA pathway is governed by 42 CFR §423.578(b) (formulary exception) and §423.602 (redetermination timelines: 7 days standard, 72 hours expedited). Note that Zepbound for obesity remains statutorily excluded under 42 USC §1395w-102(e)(2)(A) — only the Mounjaro T2DM indication is reachable on Part D.
Tactical tip: Before resubmitting, pull the EOB/denial through the Cigna provider portal and verify the rejection code. "75 — Prior Auth Required" means no PA was submitted; "76 — Plan Limitations Exceeded" means PA was submitted but failed criteria. These need entirely different responses — the first is a clerical fix via Evernorth ePA, the second triggers a formal Level 1 appeal to Cigna National Appeals Organization (NAO) in Pittsburgh within 180 days, with HbA1c lab printout, chart note bearing the E11.x code, and a prescriber attestation that no concurrent GLP-1 is in use.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →